ReviewArchives of medical science : AMS2020
Effects of antidepressants on QT interval in people with mental disorders.
Review in Archives of medical science : AMS, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 27 citations in OpenAlex.
- Risk factors for sudden cardiac death or sudden unexplained death in patients treated with clozapine: systematic review.BJPsych open · 2026Review
- Development of erectile dysfunction in men treated for major depressive disorder with selective serotonin reuptake inhibitors: a systematic review.Archives of medical science : AMS · 2026Review
- Psychiatric Medications and QTc Prolongation in the Pediatric Population.Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent · 2025Article
- A pharmacovigilance study of vortioxetine based on data from the FDA adverse event reporting system.Scientific reports · 2025Article
- Vortioxetine Can Be Used Safely to Treat Depression After Implantable Cardioverter Defibrillator Implantation for Congenital Long QT Syndrome: A Case Report.Neuropsychopharmacology reports · 2025Article
- Amphetamine Derivatives as Potent Central Nervous System Multitarget SERT/NET/HMolecules (Basel, Switzerland) · 2024Article
- Trazodone once-a-day: A formula for addressing challenges in antidepressant safety and tolerability.Neuroscience applied · 2023Review
- Association of depression phenotypes and antidepressant treatment with mortality due to cancer and other causes: a community-based cohort study.Frontiers in psychology · 2023Article
- The Risk of Fatal Arrhythmias in Post-Myocardial Infarction Depression in Association With Venlafaxine.Cureus · 2022Review
- Neurological Disorders and Risk of Arrhythmia.International journal of molecular sciences · 2020Review
- Treatment of Heart Failure Patients with Anxiolytics Is Associated with Adverse Outcomes, with and without Depression.Journal of clinical medicine · 2020Article
- Cardiovascular Considerations in Antidepressant Use.Avicenna journal of medical biotechnologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDrug-induced QT prolongation is associated with higher cardiovascular mortality. MATERIAL AND
methodsWe conducted a protocol-based comprehensive review of antidepressant-induced QT prolongation in people with mental disorders.
resultsBased on findings from 47 published randomized controlled trials (RCTs), 3 unpublished RCTs, 14 observational studies, 662 case reports of torsades de pointes, and 168 cases of QT prolongation, we conclude that all antidepressants should be used only with licensed doses, and that all patients receiving antidepressants require monitoring of QT prolongation and clinical symptoms of cardiac arrhythmias. Large observational studies suggest increased mortality associated with all antidepressants (RR = 1.62, 95% CI: 1.60-1.63, number of adults: 1,716,552), high doses of tricyclic antidepressants (OR = 2.11, 85% CI 1.10-4.22), selective serotonin reuptake inhibitors (OR = 2.78, 95% CI: 1.24-6.24), venlafaxine (OR = 3.73, 95% CI: 1.33-10.45, number of adults: 4,040), and nortriptyline (OR = 4.60, 95% CI: 1.20-18.40, number of adults: 5,298).
conclusionsEvidence regarding the risk of QT prolongation in children is sparse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.